Last updated: September 9, 2026
Fluoroestradiol F-18, marketed in the United States as Cerianna, is an FDA-approved positron emission tomography agent used to detect estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Its commercial opportunity is tied to metastatic breast-cancer imaging, PET infrastructure, radiopharmacy distribution, reimbursement, and adoption by oncology centers rather than to direct therapeutic sales.
Product-level revenue is not publicly disclosed. The financial trajectory is therefore best assessed through procedure volume, reimbursement, breast-cancer prevalence, radiopharmaceutical capacity, and competitive imaging adoption.
What is fluoroestradiol F-18 used for?
Fluoroestradiol F-18 is an F-18-labeled estrogen analog. Cerianna binds to estrogen receptors and identifies estrogen receptor-positive lesions through PET imaging. The FDA approved it on May 20, 2020, for use as an adjunct to biopsy or tissue pathology in patients with recurrent or metastatic breast cancer when estrogen receptor status is uncertain or heterogeneous.
Cerianna is an imaging agent, not a treatment. It does not replace histopathology where tissue sampling is clinically feasible. Its value is greatest when clinicians need to:
- Identify estrogen receptor-positive metastatic disease.
- Select lesions for biopsy.
- Assess disease heterogeneity.
- Resolve discordance between primary-tumor pathology and metastatic disease.
- Support treatment selection involving endocrine therapy or estrogen-receptor-directed strategies.
The product is administered intravenously and imaged with PET. Because F-18 has a relatively short half-life of about 110 minutes, commercial distribution depends on local or regional manufacturing and delivery networks.
What is the FDA regulatory status of Cerianna?
Cerianna received FDA approval under NDA 212155. The applicant was Zionexa US Corporation. GE HealthCare later acquired Zionexa and assumed commercial responsibility for the product and related molecular-imaging assets.
| Regulatory item |
Detail |
| Active ingredient |
Fluoroestradiol F-18 |
| Brand |
Cerianna |
| FDA approval |
May 20, 2020 |
| Application |
NDA 212155 |
| Product type |
Prescription diagnostic radiopharmaceutical |
| Imaging modality |
PET |
| Primary use |
Detection of estrogen receptor-positive lesions in recurrent or metastatic breast cancer |
| Regulatory pathway |
FDA New Drug Application |
| Therapeutic status |
Diagnostic imaging agent, not an oncology treatment |
| Commercial owner |
GE HealthCare following its acquisition of Zionexa |
The label states that Cerianna is intended to identify estrogen receptor-positive lesions as an adjunct to biopsy or tissue pathology. The label also warns that a negative scan does not exclude estrogen receptor-positive disease and that uptake can vary between lesions within the same patient. (U.S. Food and Drug Administration, 2020)
How large is the fluoroestradiol F-18 market?
The addressable market is narrower than the overall breast-cancer imaging market. Cerianna competes for use in selected patients with recurrent or metastatic disease, not for routine screening, primary diagnosis, or all breast-cancer staging.
The main market drivers are:
- The number of patients with metastatic breast cancer.
- The share of tumors with estrogen receptor expression.
- Availability of PET/CT scanners.
- Oncologist familiarity with molecular imaging.
- Reimbursement for the radiopharmaceutical and PET procedure.
- Availability of nearby radiopharmacy production.
- Clinical evidence linking imaging results to treatment decisions.
The strongest commercial use case is a patient whose metastatic disease may have changed biologically from the primary tumor or whose lesions are difficult to biopsy. That limits volume but increases potential clinical value per scan.
Fluoroestradiol F-18 has an advantage over conventional imaging when the clinical question concerns estrogen-receptor expression rather than anatomy alone. Its market remains constrained by the need for PET infrastructure and by competition from biopsy, immunohistochemistry, CT, MRI, FDG-PET, and other disease-specific imaging methods.
What is the financial trajectory for fluoroestradiol F-18?
No public filing separately reports Cerianna revenue, unit volume, gross margin, or operating profit. GE HealthCare reports molecular-imaging activities within broader business segments, preventing a reliable product-level revenue calculation.
The financial trajectory has four stages:
| Period |
Commercial development |
Financial implication |
| 2020 |
FDA approval |
Regulatory de-risking, but limited immediate adoption during the COVID-19 period |
| 2021-2022 |
GE HealthCare acquisition of Zionexa and commercial integration |
Expanded distribution and sales infrastructure |
| 2022-2024 |
Reimbursement development and broader clinical use |
Potential volume growth, dependent on site activation and physician adoption |
| 2025 onward |
Expansion of PET access and possible competitive supply |
Growth opportunity with pricing and utilization pressure |
Revenue is likely generated through a combination of radiopharmaceutical dose sales and related imaging activity. Dose economics are different from conventional pharmaceuticals because products are time-sensitive, locally manufactured, and exposed to delivery failures, decay losses, production scheduling, and facility utilization.
The highest-value commercial markets are metropolitan regions with:
- High breast-cancer treatment volumes.
- Academic or comprehensive cancer centers.
- PET/CT capacity.
- Radiopharmacy access within the product’s usable delivery window.
- Established molecular-imaging referral patterns.
Public financial information does not support a defensible estimate of Cerianna annual sales or a standalone valuation. Claims that assign a precise market size or revenue forecast to the product without payer, procedure, and dose-volume data are not supported by disclosed company information.
What reimbursement supports Cerianna adoption?
Medicare established a dedicated HCPCS code for F-18 fluoroestradiol under A9595. Reimbursement depends on the site of care, annual payment rules, geographic adjustments, packaging policies, and the associated PET procedure.
The economic equation for an imaging center is:
Revenue per scan minus radiopharmaceutical acquisition cost, PET/CT operating cost, staffing, scheduling expense, failed-dose risk, and referral-acquisition cost.
Commercial adoption is more likely when the scan changes management. A scan that only confirms information already available from biopsy or conventional imaging has weaker economic value. A scan that avoids an invasive biopsy or identifies discordant metastatic disease has stronger value for providers and payers.
Coverage remains a central market variable. FDA approval does not guarantee uniform commercial-payer coverage. Local coverage policies, prior authorization, medical-necessity documentation, and institutional payment arrangements can materially affect utilization.
What competitive products challenge fluoroestradiol F-18?
Cerianna has no direct FDA-approved estrogen-receptor PET competitor with equivalent positioning in the United States at the time of its approval. Its practical competitors are alternative diagnostic approaches.
| Competitor or alternative |
Primary strength |
Limitation relative to Cerianna |
| Biopsy with immunohistochemistry |
Direct tissue confirmation |
Invasive; samples one lesion and may miss heterogeneity |
| FDG-PET/CT |
Broad oncology availability |
Measures glucose metabolism, not estrogen-receptor expression |
| CT and MRI |
Structural detail and broad access |
Do not directly measure estrogen-receptor binding |
| Bone scan |
Established skeletal-disease assessment |
Limited biological characterization |
| Clinical and pathology review |
Low incremental imaging cost |
Cannot map receptor status across the body |
Cerianna’s commercial differentiation is biological characterization. FDG-PET may show active disease, while fluoroestradiol F-18 can help determine whether lesions express estrogen receptors. The two agents can therefore be complementary rather than strictly substitutive.
What patents protect fluoroestradiol F-18?
Publicly available product information does not establish a broad, commercially decisive Orange Book patent barrier for Cerianna comparable to the patent estates surrounding many oral oncology drugs or biologics.
The product’s defensibility is more likely to depend on:
- Radiochemistry and precursor technology.
- Manufacturing processes.
- Quality-control methods.
- Automated synthesis systems.
- Distribution and radiopharmacy capacity.
- Clinical know-how and physician adoption.
- Regulatory and operational scale.
A formulation patent is less likely to create durable exclusivity for a short-lived injectable radiopharmaceutical than it does for a tablet, long-acting injectable, or complex biologic. The active compound itself is also an established research radiotracer, which limits the commercial value of composition-of-matter protection unless a particular protected form, precursor, process, or use remains enforceable.
Does Cerianna have Orange Book-listed patents?
A definitive current Orange Book patent position cannot be established from the core FDA approval and labeling materials alone. No publicly disclosed Paragraph IV dispute has become a prominent market event for Cerianna comparable to disputes involving major small-molecule oncology products.
The absence of a visible Paragraph IV case does not eliminate potential patent risk. A competitor could pursue an abbreviated pathway, rely on process differentiation, or enter after regulatory and commercial barriers rather than challenge a listed patent.
When does fluoroestradiol F-18 lose exclusivity?
Cerianna’s FDA approval date was May 20, 2020. FDA new chemical entity exclusivity generally lasts four years for filing protection and five years for approval protection, subject to statutory exceptions. That period would have expired in 2025.
The key commercial exclusivity period is therefore no longer the primary barrier to competition. Any remaining protection would depend on specific listed patents, regulatory exclusivities, manufacturing controls, supply arrangements, and the practical ability of a competitor to produce and distribute an F-18 radiopharmaceutical.
There is no conventional biologic exclusivity issue because fluoroestradiol F-18 is a small-molecule diagnostic radiopharmaceutical, not a biologic. Biosimilar risk is consequently not applicable.
Which companies are challenging Cerianna?
No major public Paragraph IV challenge or litigation campaign against Cerianna has been identified in the principal FDA and public litigation materials used to assess the product.
Potential competitors include:
- Radiopharmaceutical manufacturers developing alternative estrogen-receptor PET agents.
- Contract manufacturing organizations with F-18 synthesis capacity.
- Hospital-based radiopharmacies.
- Diagnostic companies seeking broader molecular-imaging portfolios.
- Generic or multisource applicants evaluating an abbreviated approval route.
The most credible competitive threat is operational substitution: another supplier offering equivalent or near-equivalent imaging access at a lower dose price or with better geographic coverage.
What manufacturing and geographic barriers affect the market?
F-18 radiopharmaceuticals have a short commercial half-life. Manufacturing must be synchronized with patient appointments and delivery routes. This creates barriers that are operational rather than purely patent-based.
Manufacturing barriers
Key barriers include:
- Access to cyclotrons or reliable F-18 supply.
- Validated automated synthesis equipment.
- Good Manufacturing Practice compliance.
- Radiochemical purity and sterility testing.
- Dose calibration and release procedures.
- Qualified personnel.
- Reliable same-day distribution.
- Capacity to manage failed or unused doses.
Geographic coverage
Cerianna utilization is easier in regions with dense PET networks. Rural and lower-volume markets face higher per-dose logistics costs and greater risk of unused product. A supplier with strong radiopharmacy coverage can gain share without owning a stronger patent estate.
This structure favors regional manufacturing partnerships and integrated molecular-imaging networks. It also limits the likelihood of a rapid nationwide generic launch based solely on FDA approval.
What generic launch scenarios exist for fluoroestradiol F-18?
Three launch scenarios are commercially plausible.
Limited regional entry
A competitor launches in selected metropolitan areas with existing PET demand. This approach limits distribution losses and supports efficient dose production.
Hospital-based production
Large academic centers manufacture or procure the agent through institutional radiopharmacy operations. This could reduce reliance on a national supplier but requires regulatory, technical, and quality infrastructure.
Multisite commercial entry
A national radiopharmacy network offers the product across multiple regions. This is the strongest competitive model but requires substantial investment in production sites, delivery logistics, regulatory compliance, and clinical contracting.
The most likely near-term pressure is selective regional competition rather than an immediate, nationwide price collapse.
How strong is the Cerianna patent estate?
Cerianna’s patent strength appears moderate to limited relative to protected therapeutic oncology products. The product benefits from regulatory approval, brand recognition, clinical positioning, and distribution capability. Its defensibility is less clearly based on a long-dated composition-of-matter patent.
| Protection category |
Strategic assessment |
| Composition of matter |
Limited apparent commercial leverage |
| Formulation |
Likely less decisive for a short-lived injectable radiopharmaceutical |
| Method of use |
Potentially relevant, but narrow clinical labeling limits scope |
| Manufacturing process |
Potentially important if difficult to reproduce at scale |
| Regulatory approval |
Historical advantage, but core exclusivity has expired |
| Distribution |
High practical importance because of F-18 half-life |
| Clinical adoption |
Important commercial barrier |
| Biosimilar protection |
Not applicable |
The strongest durable moat is likely the combination of clinical validation, PET-site relationships, radiopharmacy infrastructure, and reliable delivery.
What litigation or settlement agreements affect Cerianna?
No major publicly reported patent litigation or settlement agreement has materially changed Cerianna’s competitive timetable. The absence of a reported settlement means there is no publicly established agreed generic-entry date comparable to settlement-driven launches in large branded-drug markets.
Commercial risk could still arise from:
- Patent litigation involving a manufacturing process.
- Contract disputes with radiopharmacy suppliers.
- Regulatory disputes over compounding or production.
- Reimbursement disputes.
- Competition involving alternative estrogen-receptor imaging agents.
How does Cerianna compare with conventional breast-cancer imaging?
Cerianna provides a receptor-specific signal. Conventional imaging provides anatomical or metabolic information. The products therefore address different clinical questions.
| Attribute |
Cerianna |
Conventional imaging |
| Biological target |
Estrogen receptor |
Anatomy, glucose metabolism, or bone turnover |
| Main use |
Receptor characterization of metastatic lesions |
Detection and structural assessment |
| Invasiveness |
Noninvasive injection and PET scan |
Usually noninvasive, except biopsy |
| Ability to assess heterogeneity |
Whole-body mapping potential |
Usually limited receptor information |
| Infrastructure |
Requires PET and radiopharmacy access |
Broader availability |
| Cost structure |
Radiopharmaceutical plus PET procedure |
Modality-dependent |
| Clinical role |
Adjunct to pathology and treatment planning |
Diagnosis, staging, monitoring, or tissue confirmation |
Key Takeaways
- Fluoroestradiol F-18 is marketed in the United States as Cerianna by GE HealthCare.
- FDA approval occurred on May 20, 2020, under NDA 212155.
- The product is used for PET imaging of estrogen receptor-positive lesions in recurrent or metastatic breast cancer.
- Product-level revenue is not publicly disclosed.
- The commercial opportunity depends on metastatic breast-cancer volume, PET capacity, reimbursement, and radiopharmacy distribution.
- FDA exclusivity associated with the 2020 approval has expired or reached its principal statutory endpoint by 2025.
- Biosimilar competition is not relevant because Cerianna is a small-molecule diagnostic radiopharmaceutical.
- No major publicly reported Paragraph IV challenge, patent settlement, or litigation event has established a generic-entry date.
- Manufacturing, geographic delivery, and clinical adoption may be more important than patent duration.
- The principal competitive risk is regional or national supply substitution by another radiopharmaceutical provider.
FAQs About Fluoroestradiol F-18
Is Cerianna a treatment for breast cancer?
No. Cerianna is a diagnostic PET imaging agent. It helps identify estrogen receptor-positive lesions and can support treatment selection, but it does not treat cancer.
Is fluoroestradiol F-18 the same as FDG-PET?
No. Fluoroestradiol F-18 targets estrogen receptors. FDG-PET measures glucose metabolism. The agents provide different biological information.
Can Cerianna replace a biopsy?
Usually not. FDA labeling positions Cerianna as an adjunct to biopsy or tissue pathology. It may help select a lesion for biopsy or clarify disease heterogeneity when tissue information is incomplete.
Is there a biosimilar version of Cerianna?
No biosimilar pathway applies. Cerianna is a small-molecule radiopharmaceutical rather than a biologic.
What is the main investment risk for Cerianna?
The main risk is limited utilization relative to broader oncology imaging products. Adoption depends on reimbursement, PET-site availability, clinician behavior, radiopharmacy logistics, and evidence that imaging changes clinical management.
References
-
U.S. Food and Drug Administration. (2020). Cerianna (fluoroestradiol F 18) injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2020, May 20). FDA approves new imaging drug to identify estrogen receptor-positive lesions. FDA.
-
Centers for Medicare & Medicaid Services. (2021). Healthcare Common Procedure Coding System: A9595, fluorine-18 fluoroestradiol, diagnostic, per study. CMS.
-
GE HealthCare. (2021). GE Healthcare completes acquisition of Zionexa. GE HealthCare.
-
National Cancer Institute. (2024). Metastatic breast cancer treatment and estrogen receptor-positive breast cancer resources. National Cancer Institute.
